Hostname: page-component-848d4c4894-x5gtn Total loading time: 0 Render date: 2024-06-12T14:50:07.179Z Has data issue: false hasContentIssue false
  • English
  • Français

Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics?

Published online by Cambridge University Press:  07 November 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Trends in Psychopharmacology
Information
CNS Spectrums , Volume 13 , Issue 4 , April 2008 , pp. 279 - 282
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Stahl, SM. Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008.Google Scholar
2.Stahl, SM. Dopamine system stabilizers, aripiprazoie, and the next generation of antipsychotics, part 1: “Goldilocks” actions at dopamine receptors. J Clin Psychiatry. 2001;62:841–842.Google Scholar
3.Stahl, SM. Dopamine system stabilizers, aripiprazoie, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry. 2001;62:923–924.Google Scholar
4.Citrome, L. A review of aripiprazoie in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2:427–443.Google Scholar
5.Bristol-Myers, Squibb. CN13B-003: a multicenter, double blind, randomized comparative study of aripiprazoie and olanzapine in the treatment of patients with acute schizophrenia (online). 2005. URL:http://ctr.bms.com/ctd.CN138003.pdf. Accessed January 16, 2006.Google Scholar
6. Results of Phase III study of bifeprunox in subjects with acute exacerbation of schizophrenia [press release]. Marietta, Ga: Solvay Pharmaceuticals; October 2007.Google Scholar
7. Forest Laboratories and Gedeon Richter. Results of Phase IIB study for RGH188 as a treatment for schizophrenia [press release/. November, 2007.Google Scholar
8.Lawler, CP, Priouleau, C, Lewis, MM, et al.Interactions of the novel antipsychotic aripiprazoie (OPC14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1939;20:612–627.Google Scholar
9.Mamo, D, Graff, A, Mizrahi, R, Shammi, CM, Romeyer, F, Kapur, S. Differential effects of aripiprazoie on D2, 5HT2 and 5HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164:1411–1417.Google Scholar
10.Thase, ME, Marcus, RN, Hennicken, D, McQuade, RD, Carson, WH, Berman, RM. Efficacy and safety of aripiprazoie as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (Study CN138-163). Paper presented at: Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 18-20, 2006; Toronto, Canada.Google Scholar
11.Berman, RM, Marcus, RN, Swanink, R, et al.Efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:843–853.CrossRefGoogle ScholarPubMed
12.Marcus, RN, Owen, R, Swanink, R, McQuade, RD, Carson, WH, Iwamoto, T. Two studies to evaluate the safety and efficacy of aripiprazole monotherapy in outpatients with bipolar I disorder with a major depressive episode without psychotic features. Paper presented at: Annual Meeting of the American Psychiatric Association. May 19-24, 2007; San Diego, Calif.Google Scholar
13.Thase, ME, Jonas, A, Khan, A, Bowden, CL, et al.Aripiprazoie monotherapy in nonpsychotic bipolar I depression. J Clin Psychopharmacol. 2008;28:13–20.Google Scholar
14.Kiss, B, Schmidt, E, Horvath, A, et al. RGH188, a D3/D2 dopamine receptor antagonist/partial agonist antipsychotic candidate: neurochemical profile. Abstract presented at: Dopamine 50 years. May 30-June 2, 2007; Goteborg, Sweden.Google Scholar
15.Adham, N, Gyertyan, IKiss, B, et al. Antidepressant-like activity of RGH188, a potential antipsychotic with D3/D2 antagonist/partial agonist properties in a chronic mild stress-induced anhedonia model. Abstract presented at: Annual Meeting of the Society of Neuroscience. November 3-7, 2007; San Diego, Calif.Google Scholar
16.Pasztor Meszaros, G, Kapas, M, Borsos, M, et al. Pharmacokinetics of RGH188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. Abstract presented at: Annual Meeting of the European College of Neuropsychopharmacology. October 13-17, 2007; Vienna, Austria.Google Scholar
17.Shim, JC, Shin, JG, Kelly, DL, et al.Adjunctive treatment with a dopamine partial agonist, aripiprazoie, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164:1404–1410.CrossRefGoogle ScholarPubMed
18.Chen, CH, Huang, MC, Lu, ML. Aripiprazoie improves metabolic adversity in olanzapine-treated schizophrenic patients. J Clin Psychopharmacol. 2007;27:516–517.Google Scholar